TMED T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF
Quote as of Oct 26, 2026 16:33 UTC · Quotes are refreshed hourly from the data provider, so during market hours a price can be up to about 1–2 hours old; each quote shows its own timestamp.
| Previous Close | 34.08 | Day Range | 34.26 – 34.33 |
| 52-Week Range | 27.60 – 36.72 | Volume | 658 |
| Avg Volume | 7.36K | AUM | $34.0M (Oct 26, 2026) |
| Expense Ratio | 0.44% | Yield (TTM) | 0.48% |
| NAV | 34.05 | Premium/Discount | +0.62% indicative |
| Inception | Jun 11, 2025 | Holdings | 121 |
| Issuer | T. Rowe | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 87283Q750 | ISIN | US87283Q7503 |
| Management | Not stated in source data | ||
About this ETF
TMED actively invests in securities of health care companies located mainly in the US but may also include foreign companies as well. Health care companies include a wide range such as biotechnology, pharmaceuticals, products and device providers, and health care service companies. Firms must be classified in the MSCI GICS health care sector. The fund employs a fundamental, bottom-up analysis and can invest in companies across any market capitalization using both growth and value strategies, typically focusing on 100-150 stocks. This includes the use of derivatives related to the fund's investment focus. The funds management team aims to outperform its respective sector index.
Description from the fund data provider · profile as of Oct 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +0.50% | -0.53% | +14.40% | +14.67% | +19.37% | — | — | — | +35.61% |
| Total return | +0.50% | -0.53% | +14.40% | +14.67% | +20.00% | — | — | — | +36.37% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 23, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.44% | Annual cost of a $10,000 investment | $44.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings list retrieved Oct 23, 2026 · The data provider's latest disclosed portfolio for this fund. Issuers publish holdings daily or monthly, so the portfolio date can be earlier; holdings are not live positions. 121 holdings stored, 25 shown.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ELI LILLY + CO COMMON STOCK | LLY.TO | 6.16% | 1.63K | $2.1M |
| 2 | UNITEDHEALTH GROUP INC COMMON STOCK USD.01 | UNH.BA | 5.43% | 4.40K | $1.9M |
| 3 | ALNYLAM PHARMACEUTICALS INC COMMON STOCK USD.01 | ALNY | 5.13% | 7.78K | $1.8M |
| 4 | INSULET CORP COMMON STOCK USD.001 | PODD | 3.73% | 8.68K | $1.3M |
| 5 | THERMO FISHER SCIENTIFIC INC COMMON STOCK USD1.0 | TMO.TO | 3.53% | 1.80K | $1.2M |
| 6 | GILEAD SCIENCES INC COMMON STOCK USD.001 | GILD.TO | 3.26% | 7.16K | $1.1M |
| 7 | INTUITIVE SURGICAL INC COMMON STOCK USD.001 | ISRG | 3.00% | 2.33K | $1.0M |
| 8 | AGILENT TECHNOLOGIES INC COMMON STOCK USD.01 | A | 2.98% | 5.92K | $1.0M |
| 9 | CENCORA INC COMMON STOCK USD.01 | COR | 2.75% | 2.80K | $949.1K |
| 10 | ELANCO ANIMAL HEALTH INC COMMON STOCK | ELAN | 2.70% | 41.09K | $932.3K |
| 11 | WEST PHARMACEUTICAL SERVICES COMMON STOCK USD.25 | WST | 2.60% | 2.27K | $896.0K |
| 12 | DANAHER CORP COMMON STOCK USD.01 | DHR | 2.40% | 3.61K | $828.9K |
| 13 | ASCENDIS PHARMA A/S COMMON STOCK DKK1.0 | ASND | 2.30% | 3.27K | $793.4K |
| 14 | CYTOKINETICS INC COMMON STOCK USD.001 | CYTK | 2.23% | 12.35K | $769.5K |
| 15 | WATERS CORP COMMON STOCK USD.01 | WAT | 2.21% | 1.67K | $760.8K |
| 16 | VAXCYTE INC COMMON STOCK USD.001 | PCVX | 1.93% | 10.57K | $664.5K |
| 17 | DEXCOM INC COMMON STOCK USD.001 | DXCM | 1.85% | 8.13K | $636.7K |
| 18 | BOSTON SCIENTIFIC CORP COMMON STOCK USD.01 | BSX | 1.79% | 13.40K | $616.5K |
| 19 | DENALI THERAPEUTICS INC COMMON STOCK USD.01 | DNLI | 1.71% | 31.62K | $590.1K |
| 20 | MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK… | MLTX | 1.68% | 47.02K | $580.3K |
| 21 | DYNE THERAPEUTICS INC COMMON STOCK USD.0001 | DYN | 1.61% | 35.22K | $555.3K |
| 22 | SHATTUCK LABS INC COMMON STOCK USD.0001 | STTK | 1.51% | 93.01K | $520.8K |
| 23 | IDEXX LABORATORIES INC COMMON STOCK USD.1 | IDXX | 1.50% | 916 | $519.2K |
| 24 | ABBOTT LABORATORIES COMMON STOCK | ABT | 1.50% | 5.03K | $515.9K |
| 25 | MCKESSON CORP COMMON STOCK USD.01 | MCK | 1.42% | 485 | $491.0K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.48% | Paid (last 12 months) | $0.1620 |
| Frequency | Irregular | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 23, 2025 | Last payment | $0.1620 (Dec 26, 2025) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 23, 2025 | Dec 23, 2025 | Dec 26, 2025 | $0.1620 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 18.75% / — | Sharpe 1Y / 3Y | 0.829 / — |
| Max drawdown 1Y / 3Y | -11.12% / — | Sortino 1Y | 1.31 |
| Beta vs S&P 500 (3Y) | 0.625 | Correlation vs S&P 500 (1Y) | 0.405 |
| Downside deviation 1Y | 11.82% | Risk-free rate used | 4.04% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 26, 2026. Formulas →
Liquidity
| Volume today | 658 | Average volume | 7.36K |
| AUM | $34.0M | Premium/Discount | +0.62% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Week | $1.0M | +3.11% | $32.5M → $34.0M |
| 1 Month | $773.0K | +2.33% | $33.1M → $34.0M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for TMED
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.